Shares of Atul has soared 9% to Rs 1,485 on BSE the company announced that it has got the US Food and Drug Administration (FDA) approval for the Dapsone manufacture facility located at Valsad, Gujarat.
“This is to intimate that the Dapsone manufacture facility located at Atul, Valsad, Gujarat has now been approved by the US FDA,” Atul said in a statement.
The company has two business segments, namely, “Life Science Chemicals” and “Performance and Other Chemicals”. The life science chemical segment comprises several manufacturing facilities which include Dapsone manufacture facility, it added.
The stock opened at Rs 1,366 and touched a record high of Rs 1,514 on BSE after the announcements. The trading volumes on the counter more than doubled with a combined around 85,000 shares changed hands till 1345 hours on BSE and NSE.
“This is to intimate that the Dapsone manufacture facility located at Atul, Valsad, Gujarat has now been approved by the US FDA,” Atul said in a statement.
The company has two business segments, namely, “Life Science Chemicals” and “Performance and Other Chemicals”. The life science chemical segment comprises several manufacturing facilities which include Dapsone manufacture facility, it added.
The stock opened at Rs 1,366 and touched a record high of Rs 1,514 on BSE after the announcements. The trading volumes on the counter more than doubled with a combined around 85,000 shares changed hands till 1345 hours on BSE and NSE.
